This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
by Zacks Equity Research
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?
by Zacks Equity Research
Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.
GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%
by Zacks Equity Research
GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA
by Zacks Equity Research
The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
by Zacks Equity Research
GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO
by Zacks Equity Research
Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.
BioMarin Presents Interim Data on BMN 250 from Phase I/II
by Zacks Equity Research
BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
by Zacks Equity Research
Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
by Zacks Equity Research
Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.
Strength Seen in Catalent (CTLT): Stock Soars 13.9%
by Zacks Equity Research
Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
by Zacks Equity Research
Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.
KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) saw its shares rise 6% in the last trading session.
Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Advanced Accelerator Applications S.A. (AAAP) moved big last session, as its shares rose over 5% on the day.
Concordia International (CXRX) Looks Good: Stock Jumps 11.4%
by Zacks Equity Research
Concordia International Corp. (CXRX) shares rose over 11% in the last trading session.
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
by Zacks Equity Research
Akebia Therapeutics (AKBA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
Moving Average Crossover Alert: Akebia (AKBA)
by Zacks Equity Research
Akebia Therapeutics, Inc. (AKBA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session
by Zacks Equity Research
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy?
by Zacks Equity Research
Akebia Therapeutics (AKBA) could be a solid choice for investors as it has seen estimates moving sharply higher over the past four weeks.
Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist
by Zacks Equity Research
On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).